---
schema_version: "secwatch.filing_event.v1"
accession: "0000728387-25-000010"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:41:02.085216+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics appoints Maya Martinez-Davis, GSK US President, to board

## Summary
- Board expanded to 6; Martinez-Davis appointed as independent director effective Sept 3, 2025.
- She serves on Compensation and Nominations Committees; receives $60K annual cash retainer plus 75K options (max $450K fair value) vesting over 36 months.
- Martinez-Davis brings 20+ years pharma experience; currently leads GSK's US commercial business since 2019.
- Her prior roles include President of biopharma Latin America at Merck KGaA and senior roles at Pfizer and Mirati board.

## SEC filing metadata
- accession: 0000728387-25-000010
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000072838725000010/0000728387-25-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000072838725000010/catx-20250902.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000728387-25-000010
- JSON: https://secwatch.observer/filing/0000728387-25-000010.json
- Plain text: https://secwatch.observer/filing/0000728387-25-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.